KEGG   DRUG: Tislelizumab
Entry
D11487                      Drug                                   
Name
Tislelizumab (USAN/INN);
Tislelizumab (genetical recombination) (JAN);
Tislelizumab-jsgr;
Tevimbra (TN)
Product
Formula
C6410H9916N1686O2009S40
Exact mass
143935.4421
Mol weight
144024.0108
Sequence
(Heavy chain)
QVQLQESGPG LVKPSETLSL TCTVSGFSLT SYGVHWIRQP PGKGLEWIGV IYADGSTNYN
PSLKSRVTIS KDTSKNQVSL KLSSVTAADT AVYYCARAYG NYWYIDVWGQ GTTVTVSSAS
TKGPSVFPLA PCSRSTSEST AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
YSLSSVVTVP SSSLGTKTYT CNVDHKPSNT KVDKRVESKY GPPCPPCPAP PVAGGPSVFL
FPPKPKDTLM ISRTPEVTCV VVAVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV
VSVLTVVHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP PSQEEMTKNQ
VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV DKSRWQEGNV
FSCSVMHEAL HNHYTQKSLS LSLGK
(Light chain)
DIVMTQSPDS LAVSLGERAT INCKSSESVS NDVAWYQQKP GQPPKLLINY AFHRFTGVPD
RFSGSGYGTD FTLTISSLQA EDVAVYYCHQ AYSSPYTFGQ GTKLEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H95, H132-L214, H145-H201, H224-H'224, H227-H'227, H259-H319, H365-H423, H'22-H'95, H'132-L'214, H'145-H'201, H'259-H'319, H'365-H'423, L23-L88, L134-L194, L'23-L'88, L'134-L'194)
  Type
Peptide
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Remark
ATC code: L01FF09
Product: D11487<US>
Efficacy
Antineoplastic, Anti-PD-1 antibody
  Disease
Esophageal squamous cell carcinoma [DS:H00017]
  Type
Monoclonal antibody
Comment
Treatment of Oesophageal squamous cell carcinoma
Target
PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
  Pathway
hsa04514  Cell adhesion molecules
hsa04660  T cell receptor signaling pathway
hsa05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
     L01FF09 Tislelizumab
      D11487  Tislelizumab (USAN/INN)
Drug groups [BR:br08330]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D11487  Tislelizumab
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    PDCD1 (PD1, CD279)
     D11487  Tislelizumab (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11487
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11487
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11487
Other DBs
CAS: 1858168-59-8
PubChem: 384585463
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system